An Australian company leading the way in how sleep disorders are treated will unveil its latest research on the international stage at the World Sleep Congress in Prague this week (October 9-11).
Brisbane sleep apnoea pioneer Oventus Medical will present results from its latest clinical trials, which support previous data that has proven the effectiveness of a new approach to treating sleep disorders.
The findings are more evidence the Oventus Airway Technology is effective for patients who suffer nasal resistance.
Oventus founder and Clinical Director Dr Chris Hart will accompany Associate Professor Danny Eckert, Principal Research Scientist at Neuroscience Research Australia (NeuRA), who will present the results at World Sleep 2017 in Prague today (Monday).
More than 2,600 people from 68 countries will meet at the international forum to advance current thinking, improve sleep health and encourage prevention and treatment of sleep disorders, including obstructive sleep apnoea (OSA). The World Health Organisation has called sleep apnoea an epidemic.
Dr Hart said key findings include that nasal resistance was found to increase when patients with sleep apnoea were lying down and that this change was larger than in previous studies with people without sleep apnoea.
“Our technology is shown to be equally effective in patients with and without nasal resistance and that’s the big difference,” he said.
This aligns with previous clinical resistance findings and is in opposition to peer- reviewed data, which indicated that increased nasal resistance may be a reason for non-response to standard Mandibular (mouthguard) Advancement Devices.
Only Oventus devices incorporate Oventus Airway Technology with its unique, patented airway that acts like a “second nose”.
Co-developed with the CSIRO, O2VentTM has brought relief to thousands of snorers and those with mild to moderate OSA.
They are particularly successful in patients who breathe through their mouth.
Dr Hart said the developments come at an exciting time as Oventus partners with Modern Dental Group in the United States and Australia to expand its network of dentists using O2VentTMdevices.
Untreated, OSA can lead to increased risk of heart attack and stroke, hypertension, Diabetes and Alzheimer’s disease.
-ENDS-
Media and interview opportunities: Dr Chris Hart, BSc. BDSc.(Hons) M.Phil.(Cantab), Oventus founder and Clinical Director
TV EDITORS, PLEASE NOTE: VNR FOOTAGE AND INTERVIEWS AVAILABLE
For more information please contact: Ernestine Lavalle, ernestine@lavalle.com.au M +61 (0) 411 691 241
About Oventus
Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth whilst alleviating multiple sites of obstruction including the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2VentTM T is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present; breathing is supplemented via the airways in the appliance. According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnea.1 Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP2. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.3
1. Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.
2. Beecroft, et al. Oral continuous positive airway pressure for sleep apnoea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003
3. Sutherland et al. Oral appliance treatment for obstructive sleep apnoea: An updated Journal of Clinical Sleep Medicine. February 2014.
